Tsai‐Shen Yang

5.0k total citations · 3 hit papers
19 papers, 3.7k citations indexed

About

Tsai‐Shen Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Tsai‐Shen Yang has authored 19 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Tsai‐Shen Yang's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Tsai‐Shen Yang is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Tsai‐Shen Yang collaborates with scholars based in Taiwan, United States and Switzerland. Tsai‐Shen Yang's co-authors include Jim Cassidy, Stephen Clarke, Werner Scheithauer, Fernando Rivera, Arié Figer, Félix Couture, Sheryl Koski, Eduardo Díaz‐Rubio, Florin Sirzén and Mikhail Lichinitser and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer.

In The Last Decade

Tsai‐Shen Yang

19 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

2008 2.3k citations Leonard B. Saltz, Stephen Clarke et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

2008 652 citations Jim Cassidy, Stephen Clarke et al. Journal of Clinical Oncology profile →
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

2013 366 citations Shukui Qin, Yuxian Bai et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tsai‐Shen Yang Taiwan	11	2.8k	1.3k	1.1k	588	579	19	3.7k
Ralph Wong Canada	18	2.8k 1.0×	953 0.7×	1.2k 1.0×	487 0.8×	513 0.9×	36	3.4k
Claus‐Henning Köhne Germany	27	3.1k 1.1×	1.1k 0.8×	1.2k 1.1×	627 1.1×	750 1.3×	75	4.3k
Giacomo Allegrini Italy	23	3.2k 1.1×	1.2k 0.9×	1.2k 1.1×	573 1.0×	651 1.1×	77	3.9k
J-Y Douillard France	7	2.8k 1.0×	839 0.6×	932 0.8×	662 1.1×	675 1.2×	9	3.4k
Silvana Chiara Italy	16	2.5k 0.9×	914 0.7×	922 0.8×	570 1.0×	702 1.2×	36	3.0k
Nicola Personeni Italy	28	2.0k 0.7×	1.1k 0.8×	943 0.8×	626 1.1×	803 1.4×	89	3.1k
A. Roth Switzerland	28	2.8k 1.0×	1.5k 1.1×	1.3k 1.2×	766 1.3×	1.0k 1.8×	55	4.0k
Petr Karásek Czechia	11	3.0k 1.1×	843 0.6×	907 0.8×	376 0.6×	630 1.1×	15	3.6k
Frank Cihon United States	18	2.5k 0.9×	920 0.7×	1.6k 1.4×	679 1.2×	329 0.6×	33	3.8k
Guy A. Van Hazel Australia	18	1.9k 0.7×	909 0.7×	913 0.8×	373 0.6×	357 0.6×	40	2.4k

Countries citing papers authored by Tsai‐Shen Yang

Since Specialization

Citations

This map shows the geographic impact of Tsai‐Shen Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsai‐Shen Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsai‐Shen Yang more than expected).

Fields of papers citing papers by Tsai‐Shen Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsai‐Shen Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsai‐Shen Yang. The network helps show where Tsai‐Shen Yang may publish in the future.

Co-authorship network of co-authors of Tsai‐Shen Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Tsai‐Shen Yang. A scholar is included among the top collaborators of Tsai‐Shen Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsai‐Shen Yang. Tsai‐Shen Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2023). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 41(21). 3663–3669. 14 indexed citations

Yeh, Kun‐Huei, Tsai‐Shen Yang, Tzu‐Chi Hsu, et al.. (2018). Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study. Annals of Oncology. 29. ix35–ix36. 2 indexed citations

Cheng, Ann‐Lii, Sumitra Thongprasert, Ho Yeong Lim, et al.. (2016). Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 64(3). 774–784. 80 indexed citations

Qin, Shukui, Yuxian Bai, Ho Yeong Lim, et al.. (2013). Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia. Journal of Clinical Oncology. 31(28). 3501–3508. 366 indexed citations breakdown →

Cohn, Allen Lee, Robin Katie Kelley, Tsai‐Shen Yang, et al.. (2012). Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(4_suppl). 261–261. 24 indexed citations

Verslype, Chris, Allen Lee Cohn, Robin Katie Kelley, et al.. (2012). Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(15_suppl). 4007–4007. 92 indexed citations

Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2008). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 26(12). 2013–2019. 2275 indexed citations breakdown →

Cassidy, Jim, Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2008). Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(12). 2006–2012. 652 indexed citations breakdown →

Chen, Jen‐Shi, Jen‐Seng Huang, Tsai‐Shen Yang, et al.. (2004). Phase I dose escalation study of oxaliplatin combined with oral tegafur???uracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs. 16(1). 47–51. 4 indexed citations

10.

Chang, John Wen‐Cheng, Kun‐Yun Yeh, Cheng-Hsu Wang, et al.. (2004). Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Research. 14(6). 537–541. 106 indexed citations

11.

Chen, J.-S., et al.. (2004). Phase I dosing-escalating study of oxaliplatin in combination with oral tegafur-uracil/leucorvin in patients with advanced gastric cancer. Journal of Clinical Oncology. 22(14_suppl). 4266–4266. 1 indexed citations

12.

Yang, Tsai‐Shen, et al.. (2003). Oxaliplatin with Weekly Bolus 5-Fluorouracil and Leucovorin in Pretreated Advanced Colorectal Cancer Patients: A Phase II Study. Chemotherapy. 49(4). 194–199. 13 indexed citations

13.

Yang, Tsai‐Shen, et al.. (2003). Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study. Anti-Cancer Drugs. 14(2). 145–151. 1 indexed citations

14.

Wang, Hung‐Ming, Shu‐Hang Ng, Cheng-Hsu Wang, et al.. (2001). Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa. Anti-Cancer Drugs. 12(4). 331–337. 7 indexed citations

15.

Yang, Tsai‐Shen, Kuan-Cheng Hsu, Reiping Tang, & Ting‐Chang Chang. (2000). Colon carcinoma with synchronous ovarian metastasis - report and discussion of five cases. Anti-Cancer Drugs. 11(4). 279–283. 13 indexed citations

16.

Yeow, Kee‐Min, Cheng‐Hsu Wang, Jen‐Shi Chen, et al.. (1999). The Groshong Peripheral Inserted Central (PIC) Catheter: Initial Experience with Ultrasound-guided Insertion. 24(2). 61–66. 1 indexed citations

17.

Chen, Jen‐Shi, Hsueh‐Erh Liu, Cheng‐Hsu Wang, et al.. (1999). Weekly 24-h infusion of high-dose 5-flurouracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs. 10(4). 355–360. 5 indexed citations

18.

Yang, Tsai‐Shen, Kuan-Cheng Hsu, Jy‐Ming Chiang, et al.. (1999). A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma. Cancer. 85(9). 1925–1930. 10 indexed citations

19.

Yang, Tsai‐Shen, et al.. (1994). Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anti-Cancer Drugs. 5(4). 480–482. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact